Catalyst Pharmaceuticals, Inc.: Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q19 net revenues of $30.9M and FY19 guidance of approx $100M. Key Firdapse trial readouts in 1H20: Phase 3 trial for MuSK-MG and SMA Type 3 proof of concept trial.
Based in...
US - South Atlantic
Clinical Stage
Phase III, Registration Stage
Disease Space
Central Nervous System, Rare Disease
Specialty Pharmaceutical
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Catalyst Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
State Street Corp. 6.48 6,676,601 22.43 13F 6/30/20
Armistice Capital LLC 6.02 6,200,000 20.83 13F 6/30/20
The Vanguard Group, Inc. 4.83 4,970,502 16.70 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 4.65 4,788,573 16.09 13F 6/30/20
BlackRock Fund Advisors 3.52 3,629,779 12.20 13F 6/30/20
Mangrove Partners 3.04 3,130,195 10.52 13F 6/30/20
BlackRock Institutional Trust Co. NA 2.79 2,869,400 9.64 13F 6/30/20
Morgan Stanley Smith Barney LLC 2.67 2,752,462 9.25 13F 6/30/20
Geode Capital Management LLC 1.53 1,574,492 5.29 13F 6/30/20
Schroder Investment Management International Ltd. 1.46 1,499,474 5.04 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.